Compare Amylx Pharmaceuticals Inc (AMLX) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Box Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Box Inc trades at $28.64 (market cap $3.97B). The key difference: Box Inc is far larger — about 2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | BOX | |
|---|---|---|
Market Cap | $1.98B | $3.97B |
Sector | Health | Technology |
52-Week High | $18.70 | $33.55 |
52-Week Low | $7.64 | $21.37 |
Enterprise Value | $1.70B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
BOX trades at $28.64, down 0.56% today, with strong analyst support (17 Buy, 10 Hold, 1 Sell) and a $37.00 consensus price target representing 29% upside. The company shows robust revenue growth from $874M in 2022 to $1.09B in 2025, with net income surging to $244.62M. Recent expansion of Box Zones in Switzerland, Israel, and Singapore (Business Wire, June 30, 2026) enhances global data governance capabilities. Technical indicators show bullish moving averages but overbought RSI levels.
BOX presents a compelling growth story with expanding profitability and strategic international expansion, though elevated valuation multiples (P/E 44.75) require continued execution. Key risks include competitive cloud storage pressures and debt levels, while institutional sentiment remains positive with significant upside to price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
